Fortress BiotechFBIO
FBIO
About: Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
Employees: 101
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
73% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 11
0.34% more ownership
Funds ownership: 17.45% [Q4 2024] → 17.79% (+0.34%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
13% less funds holding
Funds holding: 53 [Q4 2024] → 46 (-7) [Q1 2025]
22% less capital invested
Capital invested by funds: $9.77M [Q4 2024] → $7.66M (-$2.11M) [Q1 2025]
56% less call options, than puts
Call options by funds: $130K | Put options by funds: $297K
78% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 9
Research analyst outlook
We haven’t received any recent analyst ratings for FBIO.
Financial journalist opinion
Based on 3 articles about FBIO published over the past 30 days
Neutral
GlobeNewsWire
2 weeks ago
Journey Medical to Join Russell 2000® and Russell 3000® Indexes
SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or the “Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as a result of their 2025 annual Russell Index reconstitution.
Neutral
GlobeNewsWire
3 weeks ago
Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference
Emrosi™ (DFD-29; 40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) demonstrated efficacy independent of body weight differences when treating rosacea Emrosi™ (DFD-29; 40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) demonstrated efficacy independent of body weight differences when treating rosacea
Positive
Zacks Investment Research
3 weeks ago
Despite Fast-paced Momentum, Fortress Biotech (FBIO) Is Still a Bargain Stock
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Fortress Biotech (FBIO) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Neutral
GlobeNewsWire
1 month ago
Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV
National TV Segment Highlights FDA-Approved Treatment for Rosacea Segment premiered on Monday, June 9 and will be rebroadcast on Thursday, June 19, at 7:30 a.m. PT/ ET SCOTTSDALE, Ariz.
Positive
Zacks Investment Research
1 month ago
Fortress Biotech (FBIO) Is Attractively Priced Despite Fast-paced Momentum
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Fortress Biotech (FBIO) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Neutral
GlobeNewsWire
1 month ago
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics
Fortress will receive ~$28 million shortly after closing and is eligible for an additional contingent value right (CVR) of up to $4.8 million, plus a 2.5% royalty on future net sales of UNLOXCYT™ (cosibelimab-ipdl) Fortress will receive ~$28 million shortly after closing and is eligible for an additional contingent value right (CVR) of up to $4.8 million, plus a 2.5% royalty on future net sales of UNLOXCYT™ (cosibelimab-ipdl)
Negative
Zacks Investment Research
1 month ago
New Strong Sell Stocks for May 16th
FBIO, AFCG and HRZN have been added to the Zacks Rank #5 (Strong Sell) List on May 16, 2025.
Negative
Zacks Investment Research
1 month ago
Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates
Fortress Biotech (FBIO) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $1.03 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
Emrosi™ commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkpoint stockholders to approve the transaction to take place on May 28, 2025 FDA accepted New Drug Application filing for priority review of CUTX-101 to treat Menkes disease; PDUFA goal date of September 30, 2025 MIAMI, May 15, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2025. Lindsay A.
Neutral
GlobeNewsWire
1 month ago
Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late March 2025 Phase 3 Clinical Trial Results for Emrosi Published in JAMA Dermatology Emrosi Now Included in Updated National Rosacea Society Treatment Algorithms Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz.
Charts implemented using Lightweight Charts™